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Recently, research has indicated an increased risk for greater medical and emotional
comorbidity and physical health symptoms among women with an FMR1 expansion.
However, these studies have generally been limited in their ability to model multiple
risk factors associated with these symptoms by small numbers (n = 112–146) of
participants.This study used surveymethodology to examine the health experiences of 458
adult women with the premutation with and without a history of a fragile X primary ovarian
insufﬁciency (FXPOI) diagnosis. Results suggest similar ﬁndings to those reported in the
literature with regard to the frequency of medical, emotional, and reproductive experiences
of women with the premutation. In addition to expected reproductive differences, women
with a diagnosis of FXPOI were also more likely to experience dizziness, nausea, and
muscle weakness than women without a diagnosis of FXPOI. Women with and without
FXPOI were more likely to have used reproductive assistance and were more likely to have
experienced preeclampsia during at least one pregnancy than is reported in the general
population. Having comorbid depression and anxiety was predictive of increased medical
conditions and increased daily physical health symptoms.
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INTRODUCTION
Expansion of repetitions of the trinucleotide sequence of cytosine
and guanine (CGG) on the FMR1 gene is the cause of several well-
described disorders including fragile X syndrome (FXS), fragile
X tremor ataxia syndrome (FXTAS), and fragile X primary ovar-
ian insufﬁciency (FXPOI). FXS occurs in individuals who have
over 200 CGG repeats (full mutation), whereas individuals with
repeats between 55 and 200 are considered to have a premuta-
tion and are at increased risk of passing on an expansion to a full
mutation in the next generation. FXTAS and FXPOI are associated
with premutation status. In addition to these disorders, several
additional medical, emotional, and cognitive challenges have been
described as occurring at a greater frequency among individuals
with a premutation than would be expected in the general popula-
tion. These include reports of higher rates of depression, anxiety,
attention challenges, hypertension, thyroid disease, ﬁbromyal-
gia, and migraines (see Wheeler et al., 2014 for a review of these
features).
Several studies have examined associated medical and cogni-
tive features in individuals with a diagnosis of FXTAS as compared
with those without FXTAS (Coffey et al., 2008; Hashimoto et al.,
2011; Tassone et al., 2012; Yang et al., 2013), with results suggest-
ing greater risk for those with a FXTAS diagnosis. To date, only
one study (Hunter et al., 2010) has examined symptoms other
than reproductive risk for women with and without a diagno-
sis of FXPOI. FXPOI is deﬁned by premature ovarian failure,
cessation of menses before age 40, and other indicators of early
ovarian aging or dysfunction (Sullivan et al., 2011). Approxi-
mately 20% of premutation carriers will be diagnosed with FXPOI
(Sherman, 2000). Even among those at younger ages who do
not meet full criteria for FXPOI, women with a premutation
on average experience menopause 5 years earlier than controls
(Murray, 2000; Sullivan et al., 2011) and have more hot ﬂashes
(Smith et al., 2012); decreased levels of anti-Müllerian hormone
(Spath et al., 2011); increased levels of follicle stimulatinghormone
(FSH; Murray, 2000; Hundscheid et al., 2001; Sullivan et al., 2005;
Rohr et al., 2008; Welt, 2008; Spath et al., 2011); and irregular,
shorter, or skipped menstrual cycles and subfertility (Allen et al.,
2007; Welt, 2008). Hunter et al. (2010) also found an increased
risk for depression/anxiety and thyroid problems for premutation
women who had an indication of ovarian insufﬁciency, suggest-
ing, as has been hypothesized in other studies (Mondul et al.,
2005; Rodriguez-Revenga et al., 2008), that the increased risk for
emotional challenges reported for premutation carriers may be
linked to hormonal imbalances. Mid-range CGG repeats have also
been associated with both increased risk for earlier menopause
(Sullivan et al., 2005; Ennis et al., 2006; Allen et al., 2007; Tejada
et al., 2008; Spath et al., 2011) and increased risk for depression,
anxiety, and stress susceptibility (Johnston et al., 2001; Roberts
et al., 2009; Hunter et al., 2012; Seltzer et al., 2012), further sug-
gesting an association between these reproductive and emotional
risks.
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Although women with a premutation experience clear
increased risk for reproductive challenges, only one study to
date, conducted in Finland, has examined pregnancy outcomes
in a small number of premutation carriers (Kallinen et al., 2000).
A slightly higher risk for late pregnancy bleeding in the FMR1
premutation women was found compared with the general pop-
ulation, but no other concerns were noted related to the course
or outcome of pregnancy. Other than this one small study, no
other studies have examined pre-, peri-, or postnatal experiences
of carrier women. Further, no studies have examined rates of use
of reproductive assistance among carrier women.
Several environmental factors likely play a contributing role in
the relative risk for some of these reported co-morbid features.
For example, Seltzer et al. (2012) found that among premutation
carrier mothers with mid-range CGG repeats, those who expe-
rienced stressful life events in the previous year also experienced
elevated rates of depression and anxiety. Others have suggested
that environmental toxins and stressors may interact with epi-
genetic functions to contribute to increased risks for negative
outcomes (Hagerman and Hagerman, 2013).
It is also unclear as to how much the relative stress of having
a child and/or other family members with full-mutation FXS has
on these more negative outcomes. Two recently conducted stud-
ies examined some features in mothers whose child has autism in
contrast tomotherswhose child has FXS (Smith et al., 2012; Crum-
Bailey et al., 2013), with ﬁndings suggesting similar patterns of
stress and emotional challenges for premutation carrier mothers
of children with FXS and mothers of those with autism. There-
fore, although it is likely that the FMR1 expansion plays some role
in increasing susceptibility to physical and emotional challenges,
there are clearly additional environmental contributions that must
be considered in determining relative risk.
Many of the studies on individuals with a premutation have
generally been limited in their ability tomodelmultiple risk factors
associated with these symptoms by small numbers (n = 112–146)
of participants. This study used survey methodology to contribute
to knowledge regarding the premutation phenotype by describing
health experiences of a large number of women across a wide
adult age range. In addition to providing frequencies of reported
symptoms over adult age groups, we also provide a comparison
of these symptoms in women with a FXPOI diagnosis compared
with those without an FXPOI diagnosis. Finally, we examine
environmental predictors of several of these symptoms to aid
in identifying possible additional risk factors for women with a
premutation.
MATERIALS AND METHODS
DESIGN
Survey methodology was used to describe the self-reported expe-
riences with various physical, psychological, and reproductive
symptoms of adult women with an FMR1 premutation. Survey
items were based on comorbid medical and psychological diag-
nosis and daily physical health symptoms previously reported to
occur at a greater frequency among women with a premutation
(Smith et al., 2012). Participants were offered the opportunity
to complete the survey online or via telephone; the majority
completed the survey online.
PARTICIPANTS
All procedures were approved by the Institutional Review Board
(IRB) of the authors’ primary institutions. A total of 454 adult
women with the premutation completed this survey as part of
a larger national survey study on the experiences of families
affected by FXS. The number of participants included in indi-
vidual analyses varies slightly as a result of skipped items on the
survey.
Of the women with a premutation who completed the sur-
vey, 13 (3%) self-reported a diagnosis of FXTAS, 72 (16%)
self-reported a diagnosis of FXPOI, and 3 (0.006%) indicated
a history of both FXTAS and FXPOI. The rate of self-reported
FXPOI among this sample is similar to previously reported
prevalence rates among premutation carriers (Sherman, 2000).
The self-reported rate of FXTAS (3%) is lower than previ-
ously reported rates among female premutation carriers, which
is to be expected given the web-based format of this study
and lower likelihood of older individuals with complications
inherent with FXTAS being involved with a computer-based
study.
Because of the small number of women with a diagnosis of
FXTAS, these participants were removed from further analyses,
leaving a total n of 438. Frequencies of comorbid diagnoses, phys-
ical health symptoms, and reproductive experiences are reported
separately for women with no history of FXPOI (no FXPOI group;
n = 364) and those with a history of FXPOI (FXPOI group;
n = 72).
The respondents were primarily white (94%) and well edu-
cated (67% with at least a 4-year college degree), with an average
age of 48.5 years. Family income was also generally high with 41%
reporting annual incomes over $100,000. Demographic informa-
tion for individuals with and without a reported FXPOI diagnosis
is reported in Table 1.
MEASURES
Survey items included questions about whether the respondent
had ever been diagnosed or treated for seven speciﬁc medical
[thyroid disease, hypertension, autoimmune disease, heart dis-
ease, gastrointestinal (GI) issues, seizures, diabetes] and ﬁve
psychological or educational (depression, anxiety, ADHD, learn-
ing disabilities, speech/language disorder) diagnoses. They were
also asked to report on the frequency of speciﬁc physical symp-
toms (e.g., headache, fatigue, joint pain) experienced over the
previous 30 days. These symptoms were reported on a 4 point
scale (0 = never to 3 = very often). For reproductive health
items, women were asked about whether they had experienced
absent or irregular periods, early menopause, and infertility. They
were also asked about their use of reproductive assistance both
before and after learning of their own FMR1 status. Respon-
dents indicated whether they had any challenges with pregnancy
(e.g., preeclampsia), birth and delivery (e.g., length of labor),
and the postpartum period [e.g., difﬁculty breastfeeding, postpar-
tum depression (PPD)]. In other modules of the survey, women
provided information regarding family income, education level,
and number of children with and without FXS. Finally, parents
reported on the frequency and severity of aggressive behavior
as a measure of problem behavior in their children (with full
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Table 1 | Demographics of the sample with and without FXPOI.
Women without FXPOI Women with FXPOI
N 365 73
Mean age (SD) 48.63 (11.69) 48.85 (12.16)
Race
White 93.4% (341) 94.5% (69)
Nonwhite 6.6 (24) 5.5% (4)
Education
HS or less 8.0% (29) 4.1% (3)
Some college 17.9% (65) 15.1% (11)
2 year degree 8.5% (31) 6.9% (5)
4 year degree 37.4% (136) 31.5% (23)
Graduate or
professional degree
28.3% (103) 42.5% (31)
Family income
<$25,000 5.1% (18) 5.7% (4)
$25,000–50,000 16.1% (57) 11.4% (8)
$50,001–75,000 21.2% (75) 15.7% (11)
$75,001–100,000 17.8% (63) 18.6% (13)
>$1,000,000 39.8% (141) 48.6% (34)
Number of total children*
0 2.74% (10) 6.9% (5)
1 47.1% (172) 61.6% (45)
2 34.8% (127) 21.9% (16)
3+ 15.3% (56) 9.6% (7)
Number of children with full mutation or premutation FX**
0 6.6% (24) 11.3% (8)
1 68.5% (248) 78.9% (56)
2 21.6% (78) 7.1% (5)
3 3.3% (12) 2.8% (2)
Mean aggressive
behavior score (SD)
5.37 (4.27) 5.25 (3.94)
*Signiﬁcant difference between groups: X 2 = 9.62; df = 3; p = 0.02.
**Signiﬁcant difference between groups: X 2 = 10.32; df = 3; p = 0.01.
or premutation FX). For the purpose of these analyses if there
was more than one child in the family, we chose the aggres-
sive behavior score for the child with the most challenging
behaviors.
ANALYSIS
Descriptive analyses included the frequencies of responses for
women with and without FXPOI, as well as comparison tests
across age groups. Regression models were run including
all women with and without FXPOI to examine predictors
of reproductive symptoms, number of co-occurring medical
conditions, and a composite of daily physical health symp-
toms. Models were initially run separately for FXPOI and
no-FXPOI groups, as well as examining age by diagnoses
interactions with no differences in results. Therefore, we exam-
ined possible environmental predictors for increased reproductive
challenges irrespective of FXPOI diagnosis (see Table 2). Pre-
dictor variables included age, income, child aggressive behav-
iors, and presence of depression and/or anxiety (emotional
composite).
RESULTS
There were no differences in age, maternal education, race, fam-
ily income, number of children with FXS and comorbid autism,
and child aggressive behaviors between the FXPOI and no FXPOI
groups.Womenwith a diagnosis of FXPOIhad fewer total children
(X2 = 9.62; df = 3; p= 0.02) and fewer childrenwith full-mutation
or premutation FX (X2 = 10.32; df = 3; p = 0.02) than women
without a diagnosis of FXPOI (see Table 1).
COMORBID PSYCHIATRIC/EDUCATIONAL DIAGNOSES
Depression and anxiety were both reported at high rates with
around 40% of women with and without FXPOI reporting a
history of these diagnoses. Across all age groups over a third of
women reported a history of depression and/or anxiety with a
slightly higher (but not signiﬁcant) percentage of women under
30 and over 61 reporting these diagnoses. No signiﬁcant differ-
ences were found for incidence of any psychiatric or educational
diagnoses between those with and without FXPOI. No differ-
ences across age groups were found. See Figures 1 and 2 for
the percentage of women endorsing psychiatric or educational
diagnoses.
COMORBID MEDICAL DIAGNOSES
The percentage of women with a diagnostic history of the seven
medical conditions is reported separately for women with and
without a diagnosis of FXPOI in Figure 3. A little under a quarter
of women with (23.3%) and without (18.6%) FXPOI reported a
history of thyroid disorder, and nearly a third with (31.5%) and
without (22.7%) FXPOI reported a history of GI issues. There
were no signiﬁcant differences found between women with and
without a diagnosis of FXPOI on any of the medical diagnoses. All
medical conditions were reported at higher rates by older adults
(see Figure 4), with a signiﬁcant increase over age groups for
hypertension (X2 = 49.96; df = 4; p < 0.001) and thyroid disease
(X2 = 19.86; df = 4; p < 0.001).
DAILY PHYSICAL HEALTH SYMPTOMS
Fatigue was the most commonly endorsed daily health symptom
with 35% of women without FXPOI and nearly half (49.3%) of
women with FXPOI reporting experiencing fatigue often or very
often in the previous month (see Figure 5). Joint pain, muscle
pain, backache, and headaches were also endorsed as occurring
often or very often in around 20% of women. Women with a diag-
nosis of FXPOI were signiﬁcantly more likely to experience muscle
weakness (X2 = 8.84; df = 3; p = 0.03), dizziness (X2 = 12.25;
df = 3; p = 0.007), and nausea (X2 = 8.79; df = 3; p = 0.01) than
women without a diagnosis of FXPOI.
Signiﬁcant age-related differences were found for headaches
(X2 = 23.36; df = 4; p < 0.001), joint pain (X2 = 22.28; df = 4;
p< 0.001), menstrual symptoms (X2 = 27.72; df = 4; p< 0.001),
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Table 2 | Regression models of health and reproductive outcomes.
Variable Medical Conditions Daily Health Symptoms Reproductive
B (SE) p B (SE) p B (SE) p
Age
≤40 REF REF REF
41–50 0.37 (0.15) 0.014 0.27 (0.13) 0.430 0.27 (0.13) 0.043
51–60 0.58 (0.17) <0.001 0.02 (0.15) 0.744 0.02 (0.15) 0.901
≥61 1.14 (0.19) <0.001 0.10 (0.17) 0.947 0.10 (0.17) 0.561
Income
≤$50,000 REF REF REF
$50,001–$75,000 −0.31 (0.17) 0.079 −0.12 (0.16) 0.014 −0.12 (0.16) 0.461
$75,001–$100,000 −0.33 (0.17) 0.056 0.07 (0.16) 0.003 0.07 (0.16) 0.645
>$100,000 −0.57 (0.15) <0.001 −0.03 (0.14) <0.001 −0.03 (0.14) 0.812
Child Aggression score
≤2 REF REF REF
4 −0.01 (0.16) 0.936 0.16 (0.14) 0.607 0.16 (0.14) 0.273
7 0.08 (0.15) 0.581 0.09 (0.14) 0.046 0.09 (0.14) 0.503
≥8 0.11 (0.16) 0.490 0.19 (0.14) 0.053 0.19 (0.14) 0.190
Emotional conditions
0 REF REF REF
1 1.25 (0.14) <0.001 −0.18 (0.13) 0.050 −0.18 (0.13) 0.164
2 2.43 (0.13) <0.001 0.04 (0.12) <0.001 0.04 (0.12) 0.757
REF = reference category.
FIGURE 1 | Percentage of women with and without FXPOI endorsing
co-occurring psychiatric or educational conditions.
and hot ﬂashes (X2 = 18.85; df = 4; p < 0.001). Headaches,
menstrual symptoms, and hot ﬂashes decreased in the older age
groups, while joint pain tended to be endorsed more by older
women (see Figure 6).
FIGURE 2 | Percentage of women endorsing co-occurring psychiatric
or educational conditions, by age group.
Results of the regression model showed that respondents with
lower family income, a childwithmore aggression issues, andmore
co-occurring emotional conditions reported more daily physical
health symptoms (see Table 2).
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FIGURE 3 | Percentage of women with and without FXPOI endorsing co-occurring medical conditions.
FIGURE 4 | Percentage of women endorsing co-occurring medical
conditions, by age group. *Signiﬁcant increases in older age groups.
REPRODUCTIVE CHALLENGES
A similar percentage of women with and without FXPOI reported
menstrual-related daily health symptoms that occurred often or
very often. However, signiﬁcantly more women with FXPOI
reported never experiencing daily symptoms related to menstrual
issues (X2 = 13.69; df = 3; p ≤ 0.003), which likely reﬂects
the women in the FXPOI group no longer menstruating at the
time of the survey. Women with FXPOI, as a reﬂection of their
diagnosis, reported high rates of irregular or absent periods
(61.6%) early menopause (90.4%), and difﬁculty getting preg-
nant (46.6%), signiﬁcantly higher than women without FXPOI
(see Figure 7). However, approximately 20% of women without
FXPOI also reported irregular or absent periods (18.4%), and
early menopause (21.4%), and 12.6% also had difﬁculty getting
pregnant.
Although clearly women with FXPOI experience high rates
of these reproductive challenges, a signiﬁcant percentage of
women without a reported FXPOI diagnosis also endorsed these
challenges. The only moderate predictor for reproductive chal-
lenges was age, with women between 41 and 50 reporting
having ever experienced reproductive challenges more than those
under 40.
Regression models indicate that age and co-occurring depres-
sion and/or anxiety were signiﬁcant predictors of more comorbid
medical conditions. Those with family incomes over $100,000
reported experiencing fewer medical conditions (see Table 2).
USE OF REPRODUCTIVE ASSISTANCE
Women were asked to report on the use of reproductive assistance
before and after they knew about their FMR1 premutation sta-
tus (see Figures 8 and 9, respectively). Among the women with
FXPOI, 31.1% reported having used some form of reproductive
assistance before knowing their FMR1 status, and 12.9% reported
using reproductive assistance after knowing their FMR1 status. For
women without a diagnosis of FXPOI, 8.5% reported using repro-
ductive assistance before and 5.2% reported using reproductive
assistance after ﬁnding out their FMR1 status.
Before knowing their status, fertility drugs (e.g., Clomid) were
the most commonly reported reproductive assistance used by
women without FXPOI (5.8%), followed by 3.4% of women
reporting use of intrauterine insemination (IUI) or artiﬁcial
insemination (AI) and 1.3% reported use of in vitro fertilization
(IVF). After knowing their status, 3.5% of women without FXPOI
reported using IVF, 1.5% used fertility drugs, and less than 1%
used AI or IUI.
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FIGURE 5 | Percentage of women with and without FXPOI endorsing having experienced specific physical health symptoms “often or very often” in
the previous 30 days. *Signiﬁcant differences between groups.
Among women with FXPOI, the most frequently reported
reproductive assistance used was fertility drugs (e.g., Clomid;
24.4% before and 4.8% after knowing their FMR1 status). IUI
or AI was used by 10.3% of women with FXPOI, and none used
IVF before knowing their FMR1 status. After knowing their status,
4.8% of women reported using IVF, 4.8% used fertility drugs, and
1.6% used AI or IUI.
Women with FXPOI were signiﬁcantly more likely to have used
any reproductive assistance (X2 = 27.89; df = 1; p < 0.001), to
have used fertility drugs (X2 = 17.69; df = 1; p ≤ 0.001), and
to have used IUI or AI (X2 = 5.02; df = 1; p = 0.03) before
knowing their status than women without FXPOI. After knowing
their status, women with FXPOI were more likely to have used any
reproductive assistance than women without FXPOI (X2 = 4.14;
df = 1; p = 0.04).
No women with or without FXPOI reported using pre-
implantation genetic diagnoses (PGD) before knowing their
status; after knowing their status, 4.8% of women with
FXPOI and 2.4% of women without FXPOI reported using
PGD.
PRE-, PERI-, AND POSTPARTUM EXPERIENCES
Women were asked about speciﬁc experiences with each of their
pregnancies, labor, and delivery (see Figure 10): 13.4% of women
without FXPOI and 16.1% of women with FXPOI reported expe-
riencing preeclampsia or high blood pressure during at least one
pregnancy. About 28% of women without FXPOI and 21% of
women with FXPOI reported bleeding or spotting during at least
one pregnancy.
With regard to labor and delivery, about 22% of women with
and without FXPOI reported a difﬁcult delivery with at least one
child. Around a third of women in both groups reported having
had a Caesarean section, and for 40.5% of women without FXPOI
and 32.3% of women with FXPOI, labor lasted over 12 h. Women
with FXPOI reported precipitous labor (less than 2 h) at a sig-
niﬁcantly higher rate than women without FXPOI (X2 = 12.71;
df = 1; p = 0.004).
Less than 20% (18.6%) of babies born to women without
FXPOI were born before 37 weeks gestation, while 13.35% of
babies born to women with FXPOI were born premature. These
rates are similar to what is reported in the general population.
Similarly, around 6% of babies born to women with or with-
out FXPOI were born with a low birth weight. Approximately
one-quarter of women with and without FXPOI who reported
having breastfed for at least 1 week endorsed stopping primarily
because of difﬁculties for her (as opposed to difﬁculties for the
child).
Less than 10% of women with and without FXPOI endorsed
having experienced PPD. Of those who reported experiencing
PPD, 25% of women with FXPOI and 43.3% of women with-
out FXPOI endorsed having experienced it two or more times. Of
the 19 women total who experienced one episode of PPD, roughly
a third (6, 32%) reported a short duration of less than 6 weeks,
a third (7, 37%) reported a duration of 6 weeks to 6 months,
and a third (6, 32%) reported a duration of over 6 months. Of
the 14 women total who reported experiencing multiple cases of
PPD, half reported experiencing at least one PPD episode lasting
over 6 months. There were no differences between those with and
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FIGURE 6 | Percentage of women endorsing having experienced
specific physical health symptoms “often or very often” in the previous
30 days, by age group. *Signiﬁcant differences across age groups.
FIGURE 7 | Percentage of women with and without FXPOI
experiencing reproductive challenges. *Signiﬁcant differences between
groups.
without FXPOI on occurrence (X2 = 0.47; df = 1; p = 0.49) or
duration (X2 = 0.08; df = 1; p = 0.77) of PDD.
DISCUSSION
Results from this large survey study expand upon previous ﬁnd-
ings suggesting increased health risks for women with an FMR1
FIGURE 8 | Percentage of women with and without FXPOI endorsing
use of reproductive assistance before knowing their FMR1 status.
*Signiﬁcant difference between groups.
FIGURE 9 | Percentage of women with and without FXPOI endorsing
use of reproductive assistance after knowing their FMR1 status.
*Signiﬁcant difference between groups.
premutation. In addition, this study examined rates of comorbid
conditions, daily physical health symptoms, and reproductive
issues (including prenatal and postpartum experiences) of women
with and without a diagnosis of FXPOI. Further, this study exam-
ined environmental predictors of health and reproductive issues
experienced by women with the premutation.
CO-OCCURRING MEDICAL AND PSYCHIATRIC CONDITIONS
There were no signiﬁcant differences between women with and
without FXPOI on any of the comorbid medical or psychi-
atric/educational conditions. As previously reported, high rates
of depression and anxiety were endorsed in this sample, with
consistent frequencies reported across the adult age groups.
Increased risks for depression and anxiety have been described as
being related to genetic risk associated with an FMR1 expansion
(Johnston et al., 2001; Hunter et al., 2008; Roberts et al., 2009),
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FIGURE 10 | Percentage of women experiencing pre-, peri-, or postpartum issues.
with some reports noting increased risks for carrier women
prior to having a child with FXS (Roberts et al., 2009). How-
ever, other studies have noted that rates of depression and anxiety
among carrier women do not differ signiﬁcantly from mothers of
children with autism (Smith et al., 2012). Higher rates of depres-
sion and anxiety have also been reported among women with
more reproductive symptoms (Hunter et al., 2010), although in
this study we did not ﬁnd differences in rates of these psychi-
atric conditions between those with and without FXPOI. More
studies are needed to identify risks for depression and anxiety
related to genetic versus environmental factors in women with a
premutation.
Themost commonly reported co-occurringmedical conditions
for those with and without FXPOI were GI problems, thyroid
problems, and hypertension. Rates of heart disease, autoimmune
disorders (including ﬁbromyalgia), diabetes, and seizures were all
under 10% for participants in this sample, which are consistent
with national occurrence rates (Blackwell et al., 2014). As would
be expected, rates of all comorbid medical concerns, except for
seizures and GI problems, were higher for the older women.
Hypertension has been noted to occur at high rates among pre-
mutation carriers with FXTAS (Coffey et al., 2008). Among those
without FXTAS, however, the risk was no different than controls.
Similarly, in this study, rates of hypertension were not higher than
reported in national occurrence rates (Blackwell et al., 2014) and,
as in the general population, rates increased with age. Among non-
FXTAS carriers, therefore, there does not appear to be a greater
risk for hypertension than would be expected in the general adult
population. A potential increased risk for preeclampsia (discussed
further below), however, may prove to be an important variable in
determining who may be at greater risk for hypertension in later
adulthood.
Similarly, around a quarter of all women in this study reported a
history of thyroid disease. This rate is similar to previous reports of
thyroid disease in carrier women without FXTAS,which has previ-
ously been reported to be slightly, but not signiﬁcantly, higher than
control samples (Coffey et al., 2008; Hunter et al., 2010). Younger
women in this study did report rates somewhat higher than has
been reported in national occurrence rates [11 vs. 3% (Blackwell
et al., 2014)]. However, rates were more similar to what would
be expected in the general population for older adults. As in the
general population and previous studies of premutation carriers,
rates increased with age, and age was the only signiﬁcant predic-
tor of thyroid problems in this sample. Whereas it has previously
been reported that women with FXPOI may be at greater risk for
thyroid problems than those without FXPOI (Hunter et al., 2010),
we did not ﬁnd signiﬁcant differences between the groups. Addi-
tional studies are needed to examine speciﬁc genetic biomarkers,
especially in younger women, which may predict increased risk for
thyroid problems.
GI problems were also reported at relatively high rates, with
nearly a third of women with and without FXPOI endorsing these
issues. Further, of all of the medical co-occurring conditions, GI
problems were one of the only ones that did not increase across
age groups, suggesting these issues are pervasive across the adult
life span. Unfortunately, the lack of speciﬁcity of this item did
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not allow for direct comparisons with national occurrence rates.
However, Smith et al. (2012) found that carriermothers of children
with FXS reported signiﬁcantly more GI problems than mothers
of children without disabilities but not more than mothers of
children with autism. This would suggest that GI problems may
be related to stress and anxiety associated with caregiving, and
indeed, GI problems have been linked with increased stress in the
general population (Mayer, 2000). More research exploring this
health concern is needed.
DAILY HEALTH SYMPTOMS
Fatigue, joint pain, backache,muscle soreness, and headaches were
the most commonly reported daily health symptoms by women
with and without FXPOI. These same symptoms were also the
most commonly reported by Smith et al. (2012) in a daily diary
study where carrier mothers of children with FXS reported symp-
toms experienced that day via a telephone interview each night
for eight consecutive days. All of these symptoms were reported
at a greater frequency than mothers of children without disabili-
ties. The consistency in reports of these symptoms suggests these
issues are important aspects’ affecting the daily lives of FMR1
premutation mothers of children with FXS. In this sample, child
problem behaviors were predictive of daily health symptoms. Sim-
ilarly, in the Smith et al. study, these symptoms were experienced
as much or more by mothers of children with autism, suggest-
ing the increased rate of these health challenges may be due
more to stressful caregiving than to the FMR1 premutation per
se. Comorbid emotional conditions (depression and/or anxiety)
were strongly predictive of daily physical health symptoms, further
suggesting stress may be playing a major role in these symptoms.
Experiencing daily pain and fatigue is certainly likely to affect
one’s quality of life and ability to effectively parent and, there-
fore, is an important consideration both clinically and for future
research.
Fatigue is an area deserving additional focus for premutation
mothers. Fatigue was a consistently reported symptom for nearly
half of all participants across all age groups and was reported at
similar rates among women with and without FXPOI. Further,
sleep issues, including restless leg syndrome and sleep apnea, have
been reported as occurring at high rates among premutation car-
riers with and without FXTAS (Hamlin et al., 2011; Summers et al.,
2014). Fatigue has been associated with higher levels of stress and
depression and lower levels of parenting satisfaction and efﬁcacy in
mothers of children with autism (Giallo et al., 2013). It is also asso-
ciated with reduced daily functioning, clarity of thinking (Fisher
et al., 2004), and ability to cope with daily stressors (Ward and
Giallo, 2008; Giallo et al., 2013). The primary factors contributing
to fatigue and the impact it has on daily quality of life and parent–
child interactions is an important factor for future research in this
population.
Women with FXPOI were signiﬁcantly more likely to experi-
ence dizziness, nausea, and muscle weakness than women without
FXPOI. Given the only environmental difference we examined
between the two groups was the total number of children and
number of children with FX, these differences in symptoms are
most likely due to a biological factor, such as changes in estrogen
levels associated with menopause. However, they could possibly
also be related to increased risks as a result of mid-range CGG
repeats or other molecular functions. More research is needed
with regard to genetic and environmental risks for physical health
symptoms experienced by carrier women.
REPRODUCTIVE HEALTH
Results related to reproductive health were largely unsurpris-
ing and conﬁrm previously reported ﬁndings suggesting elevated
rates of reproductive risk for women with an FMR1 premuta-
tion. Consistent with the hallmark symptoms of FXPOI, women
with a FXPOI diagnosis reported high rates of reproductive chal-
lenges including irregular or absent periods, early menopause,
and difﬁculty getting pregnant. However, around 20% of women
without FXPOI reported these same symptoms, which was
higher than reports of infertility issues among the general pop-
ulation (∼6%; Blackwell et al., 2014). As has been previously
suggested (Hagerman and Hagerman, 2013), these symptoms
likely reﬂect a spectrum of involvement for premutation car-
riers, rather than a clear designation of diagnostic threshold.
Women with FXPOI were signiﬁcantly more likely to have used
reproductive assistance before and after knowing their FMR1 sta-
tus. Across all women with a premutation in this study, the
only signiﬁcant environmental predictor of reproductive chal-
lenges was age, with an expected association of women in the
typical menopausal age range (41–50) reporting having expe-
rienced more challenges than younger women. These ﬁndings
suggest that environmental factors, such as income, stress-
ful child behaviors, or increased emotional challenges are not
likely to increase risk for reproductive issues over and beyond
risk associated with the molecular changes in FMR1 for these
women.
Most experiences with pregnancy, birth, and labor were consis-
tent with numbers reported in the general population of women,
suggesting that despite increased challenges with getting pregnant,
there are generally no greater prenatal, neonatal, or postpartum
risks for women with an FMR1 premutation. One exception to
this was preeclampsia, which was reported to have occurred at
rates more than double what has been reported for the general
population (Ananth et al., 2013). Preeclampsia is considered a
multi-systemic syndrome characterized by hypertension during
pregnancy (Trogstad et al., 2011). In addition to increased nega-
tive risks for the fetus and for poorer birth outcomes, preeclampsia
also increases risk of maternal death in severe cases (Lain and
Roberts, 2002). Preeclampsia has also been suggested as a possible
risk factor for future cardiovascular issues in women in the gen-
eral population (Trogstad et al., 2011). No clear factors have been
associated with increased risk for preeclampsia, although maternal
genetic variables, environmental exposures, and paternal contri-
butions have been suggested (Trogstad et al., 2011). Given previous
conﬂicting reports of higher rates of general hypertension among
premutation carriers, this increased rate of preeclampsia should
be explored further in future studies.
LIMITATION AND FUTURE DIRECTIONS
This study has some important limitations to consider. First,
it relied completely on maternal report and memory of expe-
riences, which may have occurred several decades in the past
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(e.g., experiences with pregnancy and labor for women in their
60s). The sample was non-representative, with primarily white,
well-educated women responding. Given income was a signiﬁcant
predictor for daily health symptoms, possible health disparities
as a function of socioeconomic status are an important factor to
consider in future studies.
We were also not able to get conﬁrmation of genetic status
and do not have independent reports from medical professions
of the endorsed co-occurring conditions. Given several stud-
ies have shown an association between CGG repeats and risks
for FXPOI and other co-occurring conditions, our lack of more
detailed genetic data limits our ability to model risks for these
women. Further, all of the women in this study were parents
or family members of one or more individuals with FXS; there-
fore, we are unable to separate the impact of stressful caregiving
from the effect of the FMR1 premutation. Although for some
conditions we were able to compare the results to national occur-
rence rates, the lack of a control group limits the ability to make
conclusions regarding the relative health impact for premutation
carriers.
However, despite these limitations, this study provides further
suggestion of increased risks for medical and psychiatric condi-
tions for women with a premutation, as well as the daily health
challenges experienced by premutation carrier mothers. Further,
it expands on studies examining differences between individuals
with and without a diagnosed fragile X associated disorder and
the possible association between emotional conditions and medi-
cal diagnoses and daily health symptoms. It is also the ﬁrst study
to report a possible increased risk for preeclampsia among car-
rier women. Additional research is needed to further understand
the prevalence and severity of health features associated with the
premutation as well as the genetic and environmental factors that
contribute to the likelihood that women with a premutation will
experience these additional challenges.
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